Literature DB >> 29738584

Corneal Allogenic Intrastromal Ring Segments (CAIRS) Combined With Corneal Cross-linking for Keratoconus.

Soosan Jacob, Shaila R Patel, Amar Agarwal, Arvind Ramalingam, A I Saijimol, John Michael Raj.   

Abstract

PURPOSE: To describe a new technique for the treatment of keratoconus using corneal allogenic intrastromal ring segments (CAIRS).
METHODS: CAIRS trephined from donor cornea using a double-bladed trephine were implanted into mid-depth femtosecond laser-dissected channels in the cornea of patients with keratoconus in the 6.5-mm optic zone, followed by accelerated corneal cross-linking (A-CXL)-either conventional or contact lens-assisted CXL (A-CACXL), depending on minimum corneal thickness.
RESULTS: Twenty patients (24 eyes) with stage 1 to 4 keratoconus (Amsler-Krumeich grading) were included. Mean follow-up was 11.58 ± 3.6 months (range: 6 to 18 months). There was significant improvement in uncorrected (2.79 ± 2.65 lines; range: 0 to 8 lines) and corrected (1.29 ± 1.33 lines; range: 0 to 5 lines) distance visual acuity, spherical equivalent, simulated maximum keratometry, steepest keratometry, topographic astigmatism, anterior and posterior best fit spheres, and mean power in the 3- and 5-mm zones. No eye showed progression during the entire follow-up. All segments remained well positioned and no segment-induced complications were seen. No other major intraoperative or postoperative complications were observed.
CONCLUSIONS: This pilot study indicates that CAIRS with CXL may be a simple, safe, and effective option for treating keratoconus. Further studies are recommended to determine long-term outcomes. [J Refract Surg. 2018;34(5):296-303.]. Copyright 2018, SLACK Incorporated.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29738584     DOI: 10.3928/1081597X-20180223-01

Source DB:  PubMed          Journal:  J Refract Surg        ISSN: 1081-597X            Impact factor:   3.573


  9 in total

Review 1.  Femtosecond laser-assisted stromal keratophakia for keratoconus: A systemic review and meta-analysis.

Authors:  Andri K Riau; Hla Myint Htoon; Jorge L Alió Del Barrio; Mario Nubile; Mona El Zarif; Leonardo Mastropasqua; Jorge L Alió; Jodhbir S Mehta
Journal:  Int Ophthalmol       Date:  2021-02-20       Impact factor: 2.031

2.  Corneal remodelling and topography following biological inlay implantation with combined crosslinking in a rabbit model.

Authors:  Iben Bach Damgaard; Yu-Chi Liu; Andri Kartasasmita Riau; Ericia Pei Wen Teo; Min Li Tey; Chan Lwin Nyein; Jodhbir Singh Mehta
Journal:  Sci Rep       Date:  2019-03-14       Impact factor: 4.379

3.  Long-term viability of allogenic donor stroma.

Authors:  Emmett F Carpel; Christopher Santilli; Amanda Maltry
Journal:  Indian J Ophthalmol       Date:  2020-12       Impact factor: 1.848

Review 4.  Contact lens assisted corneal cross linking in thin ectatic corneas - A review.

Authors:  Sanjana Srivatsa; Soosan Jacob; Amar Agarwal
Journal:  Indian J Ophthalmol       Date:  2020-12       Impact factor: 1.848

5.  Comments on: Are we treating the effect and neglecting the cause of keratoconus?

Authors:  Bharat Gurnani; Kirandeep Kaur
Journal:  Indian J Ophthalmol       Date:  2021-02       Impact factor: 1.848

6.  Commentary: Femtosecond laser-assisted stromal implants for keratoconus - Customized treatment for the future!

Authors:  Soham Basak
Journal:  Indian J Ophthalmol       Date:  2021-10       Impact factor: 1.848

7.  Femtosecond laser-assisted peripheral additive stromal keratoplasty for treatment of primary corneal ectasia: Preliminary outcomes.

Authors:  Mohammadreza Jafarinasab; Yasaman Hadi
Journal:  Indian J Ophthalmol       Date:  2021-10       Impact factor: 1.848

8.  Combining Porcine Xenograft Intra-Corneal Ring Segments and CXL: a Novel Technique.

Authors:  Anastasios John Kanellopoulos; Filippos Vingopoulos
Journal:  Clin Ophthalmol       Date:  2019-12-17

Review 9.  Corneal Cross-Linking: The Evolution of Treatment for Corneal Diseases.

Authors:  Duoduo Wu; Dawn Ka-Ann Lim; Blanche Xiao Hong Lim; Nathan Wong; Farhad Hafezi; Ray Manotosh; Chris Hong Long Lim
Journal:  Front Pharmacol       Date:  2021-07-19       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.